ImmunityBio Inc.
IBRX | NASDAQ
$8.45
-$0.03 (-0.35%)
At close: Sep 21, 2026, 4:00 PM ET
$8.40
-$0.04 (-0.53%)
Pre-market:
Sep 22, 2026, 5:39 AM ET
Market Data
Market Cap $8.88B
Enterprise Value $8.53B
Beta 0.14
Average Volume 11.28M
Shares Outstanding (Diluted) 1.05B
Shares Change YoY 18.22%
Institutional Ownership 17.40%
Exchange NASDAQ
ISIN US45256X1037
Price Performance
Price Change 1M 10.0%
Price Change 3M 15.4%
Price Change 6M 4.7%
Price Change YTD 318.3%
Price Change 1Y 216.5%
Price Change 3Y 412.1%
Price Change 5Y -17.6%
1M CAGR (ann.) 15.8%
1Y CAGR (ann.) 207.3%
5Y CAGR (ann.) -3.0%
All-Time CAGR -11.9%
Valuation
PE Ratio -8.71
Forward PE 116.50
PEG Ratio 0.07
Forward PEG 0.10
PS Ratio 53.38
Forward PS 20.00
PB Ratio -8.46
P/FCF Ratio -24.21
P/Adj. FCF Ratio -21.69
P/OCF Ratio -24.85
EV/Sales 51.46
EV/EBIT -9.38
EV/EBITDA -9.60
EV/FCF -23.33
Earnings Yield -11.5%
FCF Yield -4.1%
Adj. FCF Yield -4.6%
Financial Health
Net Cash $318.66M
Total Debt $38.71M
Cash & Short-Term Investments $357.37M
Total Assets $628.5M
Current Ratio 5.72
Quick Ratio 5.70
Debt / Equity Ratio -0.78
Debt / EBITDA -0.04
Debt / FCF -0.11
OCF / Debt -9.21
Interest Coverage -3.02
Altman Z-Score -0.64
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 94.6%
Operating Profit Margin -151.9%
EBITDA Margin -535.8%
Net Profit Margin -598.6%
FCF Margin -220.5%
Adj. FCF Margin -246.2%
SBC / Revenue 25.6%
SBC Impact (per share) -11.6%
Returns
Return on Assets -157.9%
Return on Equity 135.0%
Return on Invested Capital -45.0%
Return on Capital Employed -45.6%
Return on Tangible Assets -160.9%
Historical Growth (CAGR)
Revenue CAGR 3Y 554.3%
Revenue CAGR 5Y 202.9%
Revenue CAGR 10Y 128.9%
EPS CAGR 3Y 1.2%
EPS CAGR 5Y 7.8%
EPS CAGR 10Y -12.3%
FCF CAGR 3Y 7.8%
FCF CAGR 5Y 1.1%
FCF CAGR 10Y -18.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 5
EPS Growth Next 3Y 63.2%
Revenue Growth Next 3Y 121.4%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $12
Price Target Upside 42.0%
Cash Flow
Operating Cash Flow $-356.5M
Free Cash Flow $-365.63M
Adj. Free Cash Flow $-408.11M
FCF Per Share -$0.35
OCF Per Share -$0.34
OCF/S Ratio -215.0%
Income Statement
Revenue $165.79M
Gross Profit $156.88M
Operating Income $-251.8M
EBITDA $-888.34M
Net Income $-992.36M
EPS (Diluted) -$0.97
Revenue / Employee $240.98K
Profit / Employee $-1.44M
Employees 688
Add to Watchlist
Select watchlists to add or remove IBRX